New obesity shot enters first human safety tests

NCT ID NCT07624071

Recruiting now Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called ALN-6222 in 88 adults with obesity (BMI 30-40). Participants receive a single injection of either the drug or a placebo. The main goal is to check safety and how the body processes the drug, not weight loss. It is the first time this drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ALN-6222

What this could lead to

If successful, this could lead to a new injectable treatment for obesity that helps control weight.

What could go wrong

This is a very early Phase 1 study with only 88 people. It primarily checks safety, not weight loss. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Mount Royal, H3P 3P1, Canada